At the conclusion of this activity, participants will be able to:
1. Discuss the impact of race and cultural barriers on optimal GU cancer care.
2. Evaluate financial toxicity as a barrier to optimal patient care in urologic cancer.
3. Incorporate culturally sensitive communications to ensure quality care and reduce biases across diverse patient populations.
This series is supported by independent educational grants from:
Astellas
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.
Pfizer, Inc.
Sanofi Genzyme